IN2014MN01551A - - Google Patents

Info

Publication number
IN2014MN01551A
IN2014MN01551A IN1551MUN2014A IN2014MN01551A IN 2014MN01551 A IN2014MN01551 A IN 2014MN01551A IN 1551MUN2014 A IN1551MUN2014 A IN 1551MUN2014A IN 2014MN01551 A IN2014MN01551 A IN 2014MN01551A
Authority
IN
India
Prior art keywords
geranylgeranylacetone
composition
cells
mixture
various retina
Prior art date
Application number
Other languages
English (en)
Inventor
MIYANOTakayuki
KUROSETakahiro
KATOMariyo
Yoshihiro Takai
Original Assignee
Rohto Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rohto Pharma filed Critical Rohto Pharma
Publication of IN2014MN01551A publication Critical patent/IN2014MN01551A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IN1551MUN2014 2012-02-27 2013-02-25 IN2014MN01551A (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012040779 2012-02-27
PCT/JP2013/054779 WO2013129317A1 (ja) 2012-02-27 2013-02-25 ゲラニルゲラニルアセトンを含む眼科用組成物

Publications (1)

Publication Number Publication Date
IN2014MN01551A true IN2014MN01551A (uk) 2015-05-08

Family

ID=49082514

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1551MUN2014 IN2014MN01551A (uk) 2012-02-27 2013-02-25

Country Status (7)

Country Link
US (2) US20130303624A1 (uk)
JP (2) JP5358748B1 (uk)
CN (1) CN104136018A (uk)
HK (1) HK1200112A1 (uk)
IN (1) IN2014MN01551A (uk)
TW (1) TWI564006B (uk)
WO (1) WO2013129317A1 (uk)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130303624A1 (en) * 2012-02-27 2013-11-14 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition comprising geranylgeranylacetone
WO2014129466A1 (ja) * 2013-02-19 2014-08-28 ロート製薬株式会社 網膜疾患の予防、改善、又は治療用粘膜適用剤
JP5483513B1 (ja) * 2013-02-19 2014-05-07 ロート製薬株式会社 網膜疾患の予防、改善、又は治療用粘膜適用剤
JPWO2015029925A1 (ja) * 2013-08-26 2017-03-02 ロート製薬株式会社 網膜疾患の予防、改善、又は治療剤
CN110893180A (zh) * 2018-09-12 2020-03-20 厦门信力康生物技术有限公司 替普瑞酮及其衍生物作为制备治疗毒品成瘾和防止复吸药物的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06192073A (ja) * 1992-12-24 1994-07-12 Eisai Co Ltd 細胞分化誘導剤
JPH08133967A (ja) * 1994-11-02 1996-05-28 Eisai Co Ltd ドライアイ治療剤
JP2000319170A (ja) * 1999-03-05 2000-11-21 Eisai Co Ltd テプレノン含有点眼剤
US20050009772A1 (en) * 2003-05-06 2005-01-13 The Regents Of The University Of California Methods and compositions for the treatment of glaucoma and other retinal diseases
JP5027425B2 (ja) * 2006-02-17 2012-09-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 ゲラニルゲラニルアセトンを有効成分として含むチャンネル病治療剤
CN1903188B (zh) * 2006-08-03 2011-07-27 首都医科大学附属北京同仁医院 替普瑞酮在制备预防和/或治疗青光眼所致外侧膝状体神经元损害的药物中的应用
CN103052619A (zh) * 2010-09-01 2013-04-17 科约特制药公司 治疗神经退行性疾病的方法
CN102627539B (zh) * 2011-10-19 2014-04-16 利安隆博华（天津）医药化学有限公司 一种生产全反式替普瑞酮的方法
US20130303624A1 (en) * 2012-02-27 2013-11-14 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition comprising geranylgeranylacetone

Also Published As

Publication number Publication date
US20140350119A1 (en) 2014-11-27
JP5358748B1 (ja) 2013-12-04
WO2013129317A1 (ja) 2013-09-06
CN104136018A (zh) 2014-11-05
US20130303624A1 (en) 2013-11-14
JPWO2013129317A1 (ja) 2015-07-30
TW201340963A (zh) 2013-10-16
TWI564006B (zh) 2017-01-01
JP2013213050A (ja) 2013-10-17
HK1200112A1 (en) 2015-07-31

Similar Documents

Publication Publication Date Title
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
PE20150223A1 (es) Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
IN2015DN00544A (uk)
CA2840307C (en) Progenitor cells of mesodermal lineage
IN2014MN01551A (uk)
SG10201809290SA (en) Compositions and Methods to Treating Hemoglobinopathies
IN2014DN10386A (uk)
SG194718A1 (en) Novel compounds as modulators of protein kinases
IL234101B (en) Preparations containing acamprosate and baclofen for use in the treatment of Parkinson's disease
MX2015016741A (es) Inhibidores de pi3 cinasa delta y gama selectivos duales.
MX2013004062A (es) Analogos de ciclosporina.
IN2014MN01552A (uk)
IN2014MN01553A (uk)
MX362854B (es) Siarn y su uso en los metodos y composiciones para el tratamiento y/o prevencion de enfermedades de los ojos.
MX2016000313A (es) Estabilizadores de luz novedosos.
IN2014DN07326A (uk)
NZ713129A (en) Oxprenolol compositions for treating cancer
MX355668B (es) Uso de un extracto de mirto como un agente anti-biopelicula contra propionibacterium acnes.
MX2017004649A (es) Formulaciones nanoestructuradas para el suministro de silibinina y otros ingredientes activos para tratar enfermedades oculares.
MX2014004709A (es) Composicion para uso en la promocion de absorcion de magnesio y/o retencion de magnesio.
WO2015024577A3 (fr) Composition a base de safranal
GB201114230D0 (en) Addition copolymers and their use
MX2014014839A (es) Terapias sinergicas de cannabidiol con hipotermia para neuroproteccion.
PH12015501109A1 (en) Novel compounds as diacylglycerol acyltransferase inhibitors
UA79527U (en) remineralization gel with hydroxyapatite